Overview

Huntington's Disease (HD) is an autosomal disease characterized by the aggregation of proteins containing long stretches of consecutive polyglutamine (polyQ), which are encoded by a mutated huntingtin gene (htt). These proteins are called human huntingtin protein, polyQ-hHtt. HD victims suffer from motor and cognitive dysfunction, which lead to dementia and subsequent death.

The Origins of polyQ-hHtt

The expression of the HD protein, polyQ-hHtt, is a result of the expansion of the trinucleotide sequence, CAG, in the htt gene. The expansion to 35 or more CAG triplets results in production of polyQ-hHtt. The polyQ domain of polyQ-hHtt causes misfolding of the protein, making it prone to self-aggregation. Although the aggregates are predominantly nuclear, some aggregates form outside of the nucleus. These aggregates contribute to neuronal degeneration and the progression of HD.

The Origins of polyQ-hHtt

Peptides in HD Therapeutic Research

Similar to the peptides of Alzheimer's Disease, Huntington's Disease peptides can be used for:

  • The design of aggregative inhibitors of polyQ-hHtt.
  • The development of vaccines to promote immune clearance of aggregative polyQ-hHtt proteins.
  • The study of polyQ-hHtt dynamics.
View peer-reviewed huntingtin peptide research publications that cite GenScript Custom Peptide Synthesis Services

Huntington's Disease Peptide Research Toolbox

Custom PolyQ-hHtt Fragment Peptide Synthesis

  • GenScript's PepPower™ synthesis platform can synthesize polyQ-hHtt fragment peptide sequence.

Custom Peptide Solubility Testing

  • >Custom Peptide Solubility TestingPersonalized solubility test and report prepared by our peptide synthesis experts to help you maximize dissolution of your custom peptide order.

REQUEST A QUOTE